Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 study

AIDS Research and Human Retroviruses

Volumn 29, Issue 6, 2013, Pages 938-948

  Kelesidis, Theodoros ^a   Kendall, Michelle A ^b   Yang, Otto O ^a   Hodis, Howard ^c   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RANK LIGAND; RISK FACTORS;

EID: 84877847977     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0305     Document Type: Article

References (45)

1. D'Amelio P, Isaia G, and Isaia GC: The osteoprotegerin/ RANK/RANKL system: A bone key to vascular disease. J Endocrinol Invest 2009;32:6-9
2. Venuraju SM, Yerramasu A, Corder R, and Lahiri A: Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010;55:2049-2061
3. Haynes DR, Barg E, Crotti TN, et al.: Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 2003;42:123-134
4. Kleemann R, Zadelaar S, and Kooistra T: Cytokines and atherosclerosis: A comprehensive review of studies in mice. Cardiovasc Res 2008;79:360-376
5. Mohammadpour AH, Shamsara J, Nazemi S, Ghadirzadeh S, Shahsavand S, and Ramezani M: Evaluation of RANKL/ OPG serum concentration ratio as a new biomarker for coronary artery calcification: A pilot study. Thrombosis 2012;2012:306263
6. Parhami F, Garfinkel A, and Demer LL: Role of lipids in osteoporosis. Arterioscler Thromb Vasc Biol 2000;20:2346-2348
7. Nabel EG: Cardiovascular disease. N Engl J Med 2003;349: 60-72
8. Graham LS, Parhami F, Tintut Y, Kitchen CM, Demer LL, and Effros RB: Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss. Clin Immunol 2009;133:265-275
9. Graham LS, Tintut Y, Parhami F, et al.: Bone density and hyperlipidemia: The T-lymphocyte connection. J Bone Miner Res 2010;25:2460-2469
10. Currier JS: Update on cardiovascular complications in HIV infection. Top HIV Med 2009;17:98-103
11. Currier JS, Kendall MA, Henry WK, et al.: Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007;21:1137-1145
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
13. Lehmann E: Nonparametrics: Statistical Methods based on Ranks. Holden-Day, San Francisco, 1975
14. Kelesidis T, Kendall MA, Yang OO, Hodis HN, and Currier JS: Biomarkers of microbial translocation and macrophage activation: Association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012;206: 1558-1567
15. Fakruddin JM and Laurence J: Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): Implications for HIV pathogenesis. Clin Exp Immunol 2004;137: 538-545
16. Fakruddin JM and Laurence J: HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005;150:67-78
17. Jang JJ, Schwarcz AI, Amaez DA, et al.: Elevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: A cross-sectional study. J Int AIDS Soc 2010;13:12
18. Gibellini D, Borderi M, de CE, et al.: Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line. New Microbiol 2010;33:109-115
19. Fakruddin JM and Laurence J: HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-Talk. J Biol Chem 2003;278: 48251-48258
20. Gibellini D, Re MC, Ponti C, et al.: HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity. J Cell Physiol 2005;203:547-556
21. Brown TT, Ross AC, Storer N, Labbato D, and McComsey GA: Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: Tenofovir versus nontenofovir regimens. Antivir Ther 2011;16:1063-1072
22. Mora S, Zamproni I, Cafarelli L, et al.: Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS 2007;21:1129-1135
23. Gibellini D, Borderi M, de CE, et al.: RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 2007;79: 1446-1454
24. Hwang JJ, Wei J, Abbara S, Grinspoon S, and Lo J: Receptor activator of nuclear factor kappa B ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. J Acquir Immune Defic Syndr 2012;61(3):359-363
25. D'Amelio P, Isaia G, and Isaia GC: The osteoprotegerin/ RANK/RANKL system: A bone key to vascular disease. J Endocrinol Invest 2009;32:6-9
26. Seminari E, Castagna A, Soldarini A, et al.: Osteoprotegerin and bone turnover markers in heavily pretreated HIVinfected patients. HIV Med 2005;6:145-150
27. Chan BY, Buckley KA, Durham BH, Gallagher JA, and Fraser WD: Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem 2003;49:2083-2085
28. Wagner D and Fahrleitner-Pammer A: Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help? Wien Med Wochenschr 2010;160:452-457
29. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, and Aukrust P: Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess -possible role in bone homeostasis. Eur J Endocrinol 2001;145:685-690
30. Currier JS and Havlir DV: Complications of HIV disease and antiretroviral therapy. Top HIV Med 2009;17:57-67
31. SchoppetM, Schaefer JR, and Hofbauer LC: Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003;107:e76
32. Crisafulli A, Micari A, Altavilla D, et al.: Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 2005;109:389-395
33. Findlay D, Chehade M, Tsangari H, et al.: Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther 2008;10:R2
34. Fakruddin JM and Laurence J: HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-Talk. J Biol Chem 2003;278: 48251-48258
35. Yin MT, Modarresi R, Shane E, et al.: Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporos Int 2011;22:1459-1468
36. Luegmayr E, Glantschnig H, Wesolowski GA, et al.: Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/ lipoproteins. Cell Death Differ 2004;11:S108-S118
37. Hada N, Okayasu M, Ito J, et al.: Receptor activator of NFkappaB ligand-dependent expression of caveolin-1 in osteoclast precursors, and high dependency of osteoclastogenesis on exogenous lipoprotein. Bone 2012;50:226-236
38. Oh ES, Rhee EJ, Oh KW, et al.: Circulating osteoprotegerin levels are associated with age, waist-To-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005;54:49-54
39. Kelesidis T, Currier JS, Huynh D, et al.: A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res 2011;52:2341-2351
40. Patel S, Drew BG, Nakhla S, et al.: Reconstituted highdensity lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009; 53:962-971
41. Currier JS: Update on cardiovascular complications in HIV infection. Top HIV Med 2009;17:98-103
42. Kelesidis T, Reddy ST, Huynh D, et al.: Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis 2012;11:87
43. Zhang M, Gao X, Wu J, et al.: Oxidized high-density lipoprotein enhances inflammatory activity in rat mesangial cells. Diabetes Metab Res Rev 2010;26:455-463
44. The interplay of the osteoprotegerin/RANKL axis and dysfunctional HDL in HIV-positive adults: ACTG NWCS 332/A5078 study. Presented at the XIX International AIDS Conference 2012, Washington, DC, June 2012 [Abstract THAB0201
45. Van CA and Golledge J: Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204(2): 321-329